VICTORIA, British Columbia - ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a company specializing in AI-driven biotherapeutic research, has announced the acquisition of the LSA instrument platform from Carterra, a provider of high-throughput screening and characterization solutions.
This acquisition is aimed at enhancing ImmunoPrecise's capabilities in antibody characterizations and expediting its in vitro characterizations for clients and partners.
The LSA instrument is designed to perform surface plasmon resonance-based antibody characterizations, which are essential for analyzing protein interactions. This technology aligns with ImmunoPrecise's approach to diversity- and data-driven drug discovery, potentially enabling the company to process a larger amount of data for its AI models.
Jennifer Bath, PhD, CEO and President of ImmunoPrecise, highlighted the strategic value of integrating LSA technology with the company's LENSai platform, suggesting it could lead to a faster and more cost-effective drug discovery workflow. Tim Germann, Chief Commercial Officer at Carterra, expressed enthusiasm for the partnership with ImmunoPrecise, noting the LSA's role in facilitating AI in antibody discovery.
ImmunoPrecise's acquisition is part of its broader strategy to expand its contract research organization capabilities, leveraging technology to drive innovation and efficiency in AI-driven drug design.
The company's proprietary HYFTs (highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing technologies) are expected to benefit from the large datasets generated by the LSA instrument.
The press release, however, includes forward-looking statements which are based on assumptions by ImmunoPrecise's management and are subject to various risks and uncertainties that could cause actual results to differ materially from those projected.
The information in this article is based on a press release statement from ImmunoPrecise Antibodies Ltd.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.